Literature DB >> 8606069

Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1.

R Shimonkevitz1, E Boen, S Malmstrom, E Brown, J M Hurley, B L Kotzin, M Matsumura.   

Abstract

Murine monoclonal antibodies (MAbs) specific for toxic shock syndrome toxin 1 (TSST-1), a bacterial superantigen, showed the ability either to detect TSST-1 bound to histocompatibility locus antigen (HLA)-DR molecules or to inhibit TSST-1 binding to HLA-DR. A MAb capable of detecting DR-bound TSST-1 could also inhibit the toxin-induced activation of a T-cell receptor Vbeta15-expressing murine T-cell hybridoma. Alternatively, MAbs with specificity for the HLA-DR association site could present TSST-1 in vitro, stimulating CD4+ human T cells to proliferate. These functional activities correlated directly with with MAb specificity for HLA-DR versus T-cell receptor Vbeta interaction sites on TSST-1 as determined by reactivity with a panel of recombinant TSST-1 mutant molecules. Therefore, these MAbs discriminate the superantigen functional sites on the TSST-1 molecule and constitute reagents with the property of being potent modulators of the toxic activity of TSST-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606069      PMCID: PMC173894          DOI: 10.1128/iai.64.4.1133-1139.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Structure of toxic shock syndrome toxin 1.

Authors:  G S Prasad; C A Earhart; D L Murray; R P Novick; P M Schlievert; D H Ohlendorf
Journal:  Biochemistry       Date:  1993-12-21       Impact factor: 3.162

2.  Staphylococcus-mediated T-cell activation and spontaneous natural killer cell activity in the absence of major histocompatibility complex class II molecules.

Authors:  S K Chapes; S M Hoynowski; K M Woods; J W Armstrong; A A Beharka; J J Iandolo
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

3.  Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.

Authors:  K R Acharya; E F Passalacqua; E Y Jones; K Harlos; D I Stuart; R D Brehm; H S Tranter
Journal:  Nature       Date:  1994-01-06       Impact factor: 49.962

Review 4.  Superantigens and their potential role in human disease.

Authors:  B L Kotzin; D Y Leung; J Kappler; P Marrack
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

5.  Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome.

Authors:  P F Bonventre; H Heeg; C Cullen; C J Lian
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

6.  Immunobiologic and biochemical properties of mutants of toxic shock syndrome toxin-1.

Authors:  D L Murray; G S Prasad; C A Earhart; B A Leonard; B N Kreiswirth; R P Novick; D H Ohlendorf; P M Schlievert
Journal:  J Immunol       Date:  1994-01-01       Impact factor: 5.422

7.  TCR V beta family repertoire and T cell activation markers in Kawasaki disease.

Authors:  B A Pietra; J De Inocencio; E H Giannini; R Hirsch
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

8.  Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.

Authors:  D Y Leung; H C Meissner; D R Fulton; D L Murray; B L Kotzin; P M Schlievert
Journal:  Lancet       Date:  1993-12-04       Impact factor: 79.321

9.  Monoclonal antibodies defining functional sites on the toxin superantigen staphylococcal enterotoxin B.

Authors:  A R Hamad; A Herman; P Marrack; J W Kappler
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

10.  Mutations defining functional regions of the superantigen staphylococcal enterotoxin B.

Authors:  J W Kappler; A Herman; J Clements; P Marrack
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  3 in total

1.  The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental Staphylococcus aureus arthritis.

Authors:  M Verdrengh; W Kum; A Chow; A Tarkowski
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

2.  Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody.

Authors:  L T Pang; W W Kum; A W Chow
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Transcytosis of staphylococcal superantigen toxins.

Authors:  A R Hamad; P Marrack; J W Kappler
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.